Christine M. Walko graduated with her Pharm.D. degree from Duquesne University in Pittsburgh, Pennsylvania, and completed a pharmacy practice residency at the Medical College of Virginia/VCU in Richmond, Virginia, and a hematology/oncology specialty residency at the University of North Carolina (UNC). She stayed at UNC to complete a 2-year academic oncology fellowship focused on drug metabolism and translational research before taking an Assistant Professor position at UNC in the Division of Pharmacotherapy and Experimental Therapeutics until being recruited to Moffitt Cancer Center in January 2014 to assist with starting the institution’s first Precision Medicine Program. Dr. Walko is now a Senior Member in the Department of Pathology at Moffitt Cancer Center, Program Leader for Precision Medicine and an Attending on the Precision Medicine Clinical Service. She is also a Co-Chair for the ASCO TAPUR trial Molecular Tumor Board (MTB) and variant expert for the nationwide SWOG Precision Medicine trial focused on the clinical utility of Molecular Tumor Boards in Community Oncology Practices. Her research focus is on optimizing drug therapy using pharmacogenomics and pharmacokinetics to personalize intravenous and oral anticancer therapy for patients with cancer.